Apertome Therapeutics · RNA medicines for fibrosis
Skip to content
RNA medicines for fibrosis

RNA medicines for the cells that drive fibrosis.

The Apertome Engine, our proprietary platform, reads coding and non-coding RNA cell type by cell type to find targets that protein-focused drug discovery misses. Liver fibrosis is our first program.

3 RNA classes, coding and non-coding
110k+ genes ranked by cell type
69 cell-type-specific targets prioritized
01 / The problem

Fibrosis is where chronic disease ends. Drug discovery has been looking at a fraction of the genome.

Scar tissue replaces working tissue in the liver, lung, kidney and heart, building toward cirrhosis, organ failure and transplant. Approved therapies slow the injury that drives scarring, but none switches off the scar-forming program itself. Every approved therapy was built on a protein target, and less than 2% of the genome codes for protein.

The rest is transcribed into RNA that helps decide which cells turn fibrotic. Much of it is specific to a single cell type, which makes it both a precise target and easy to miss.

Drug targets today
<2%Protein-coding. Where most drugs are aimed. ~98%Non-coding, including thousands of RNAs that regulate disease.
Each rung is 1% of the human genome.
02 / Why RNA

Today's drugs reach 1 in 5 genes. RNA reaches the rest.

Small molecules need a pocket. Biologics stay outside the cell. RNA needs only a sequence. Of 20,300 protein-coding genes, only 4,479 are druggable.1 RNA medicines act on the instructions inside the cell.

Druggable genes4,4791
by small molecules or biologics
RNA medicinesAny transcript
coding and non-coding, by base pairing
Small molecules Biologics RNA medicinesOur modality {{ row.label }} {{ row.sm.v }}{{ row.sm.d }} {{ row.bio.v }}{{ row.bio.d }} {{ row.rna.v }}{{ row.rna.d }}
{{ cc.name }}
{{ it.label }} {{ it.v }} {{ it.d }}
If it is transcribed, it can be reached. RNA medicines bind their target by base pairing, which brings the non-coding 98% of the genome within reach.
Sequence, not structure. A lead is designed directly from the target's sequence, with no search for a binding pocket.
Delivered to the right cell. Targeting conjugates take RNA medicines into a chosen cell type. GalNAc carries seven of the eight approved siRNAs to hepatocytes.6
Twice a year. Approved siRNAs are dosed as rarely as twice a year.5

Making the drug is no longer the hard part. Choosing the target is.

See how we choose
Sources (6)
  1. 1 Finan et al., Sci Transl Med 2017 ↗4,479 of 20,300 protein-coding genes are drugged or druggable.
  2. 2 Uhlén et al., Science 2015 ↗About 3,000 secreted and 5,500 membrane genes. Antibody drugs usually cannot cross the cell membrane.
  3. 3 Paul et al., Nat Rev Drug Discov 2010 ↗ · Kelley, Nat Biotechnol 2020 ↗Small molecules: target-to-hit 1.0, hit-to-lead 1.5, lead optimization 2.0 years. Antibody identification usually takes several months.
  4. 4 Kim et al., N Engl J Med 2019 ↗Milasen: design, cell screen, toxicology and first dose within one year.
  5. 5 Approved siRNA labelsPatisiran is delivered by lipid nanoparticle; the other approved siRNAs are GalNAc conjugates.
  6. 6 Lipitor label ↗ · Repatha label ↗ · Leqvio label ↗Atorvastatin once daily; Repatha every 2 weeks or monthly; Leqvio at 0 and 3 months, then every 6 months. Repatha and Leqvio both act on PCSK9 in the liver.
03 / Our first program

Our first program: liver fibrosis

Fibrosis is the shared end point of chronic disease in the liver, lung, kidney and heart, and no approved medicine switches off the scar-forming program itself.

In liver fibrosis, the Apertome Engine ranked more than 110,000 genes and prioritized 69 cell-type-specific targets for our first program.

View the program
{{ funnelA }} genes, coding and non-coding
Selected for Cell-type specificityFibrosis associationDruggability
{{ funnelB }} cell-type-specific targets
Proof of concept

TILAM

A lncRNA published in Hepatology (2024). TILAM was not discovered by the Apertome Engine. It shows that a cell-type-specific non-coding RNA can drive fibrosis and be targeted, the premise our platform and fibrosis program are built on.

TILAM · Proof of concept
{{ st.title }}{{ st.sub }}
Human data

Human patient data

Liver biopsiesBlood samplesClinical dataEvery disease stage

We have access to liver fibrosis patients across the stages of the disease. Every prioritized target will be tested in patient tissue before a molecule is designed.

04 / The Apertome Engine

Inside the Apertome Engine

Our approach
Whole transcriptome

Three RNA classes, coding and non-coding, scored side by side in the same single-cell and bulk RNA data.

Cell-type precision

Targets are ranked by how specific they are to the cells driving disease, then matched to delivery into that cell type, so the medicine acts where it matters and spares healthy tissue.

Repeatable across diseases

The same engine applies to any tissue with single-cell data. Fibrosis is our first indication.

Partnering

Build RNA medicines for the cells that drive disease.

Our approach · The Apertome Engine

Every RNA. Every cell type. The targets that drive disease.

Disease starts when specific cells change state. The Apertome Engine finds the RNA that controls that change, cell type by cell type, and pairs each target with delivery into the cell type that expresses it.

01 / Biology

Beyond the 2%

Protein-coding genes are a small part of the genome. The non-coding majority is the instruction layer that sets cell identity and behavior. We annotate and quantify three RNA classes, mRNA, long non-coding RNA and microRNA, in the same single-cell and bulk RNA data, so every candidate is compared on equal terms.

Coverage Three RNA classes, one search
{{ r.kind }} {{ r.abbr }} {{ r.name }}
02 / The Apertome Engine

Map. Rank. Match. Validate.

01

Map

We profile healthy and diseased tissue with single-cell sequencing to resolve cell types, and bulk RNA sequencing for depth. The Apertome Engine's proprietary annotation captures coding and non-coding transcripts that standard references miss. Every RNA is assigned to the cell types that express it, from stellate-cell drivers of fibrosis to hepatocyte-specific lncRNAs.

{{ r.abbr }} {{ row.name }}
LowHigh cell-type specificity
02

Rank

Every transcript is scored on cell-type specificity, association with disease and druggability by RNA medicines. Specificity comes first: a target confined to the disease-driving cell is a target with fewer side effects in healthy tissue.

110k+genes · ~19k coding + ~91k non-coding
Ranked byCell-type specificityDisease associationDruggability
69
prioritized targets · 46 lncRNA + 23 protein-coding
03

Match

Each target is paired with a delivery route into the cell type that expresses it. We start in hepatocytes, where GalNAc conjugates already deliver approved RNA medicines, and extend to stellate cells as delivery to them matures.

Cell typeDeliveryStatus
HepatocyteGalNAc conjugateClinically proven · first
Stellate cellTargeted conjugatesEmerging · next
04

Validate

Each target is silenced in human liver organoids, with chemistry matched to where the RNA sits: antisense oligonucleotides for nuclear lncRNAs, siRNA for RNA in the cytoplasm. We then measure whether the scarring program switches off and reverses, and targets that do advance to in vivo models.

TargetCell-type-specific RNA
MedicineASO or siRNA
ModelHuman liver organoid
ReadoutScarring reversed
03 / Advantages

The Apertome advantage

Non-coding first

lncRNAs are 46 of our 69 prioritized targets. Most pipelines never score them because standard annotations miss them.

Specificity before potency

A target confined to the disease-driving cell starts with a safety advantage. We rank for that first.

Built to be delivered

Every target is matched to a delivery route into its cell type, so the shortlist is a list of medicines that can reach their cells.

Human data first

Every prioritized target is tested in patient tissue before a molecule is designed.

04 / Proof of concept

TILAM

TILAM is a long non-coding RNA. Published in Hepatology (2024), it is expressed predominantly in the stellate cells that make the scar in the injured liver, and depleting it protected against fibrosis in human stellate cells, human liver organoids and mouse models.

It validates the RNA class and the indication. It is the reference point for the cell-type-specific targets the Apertome Engine now finds at scale.

Read the TILAM paper ↗
TILAM · Proof of concept
{{ st.title }}{{ st.sub }}
05 / Foundations

Built on the founder's published tools

Single-cell lncRNA · Scientific Reports, 2025
Singletrome

A genome annotation of 110,599 genes, protein-coding and lncRNA, built for single-cell data. It resolves lncRNA expression by cell type and showed lncRNAs alone can identify cell types and disease.

Read paper ↗
Small RNA-seq · BMC Bioinformatics, 2018
Oasis 2

A web application for detection, differential expression and classification of small RNAs in sequencing data, including novel miRNAs across 14 organisms.

Read paper ↗
Small RNA atlas · Nucleic Acids Research, 2020
SEAweb

The Small RNA Expression Atlas: over 4,200 published samples across 10 organisms, re-analyzed and searchable, with 591 tissue-specific miRNAs identified.

Read paper ↗
Program

Silencing the genes that drive liver fibrosis.

Our first program silences disease-driving genes in specific liver cell types, using RNA specific to those cells. We start where RNA delivery is already clinically proven, so the path to the clinic is shorter.

Pipeline
Program
Indication
Target discovery
Target validation
Lead optimization
IND-enabling
Clinical
Liver fibrosis programCell-type-specific RNA targets
Liver fibrosis
Next indicationsAdditional fibrotic indications
Fibrosis
Active program Planned
01 · Indication

Liver fibrosis

Fibrosis stage is the strongest predictor of liver-related death.1 The two approved MASH therapies act upstream, on the metabolic injury that provokes scarring. No approved therapy switches off the scar-forming program itself. Our target patients are adults with MASH and moderate to advanced fibrosis (F2–F3), the stage at which fibrosis drives outcomes and treatment is indicated.

02 · Cell type

Hepatocytes first

Now Hepatocytes GalNAc conjugates · Clinically proven
Next Stellate cells Targeted conjugates · Emerging

Proven route. Our first targets are expressed in hepatocytes, where delivery of RNA medicines is clinically validated: GalNAc conjugation is used by seven of the eight approved siRNAs. In phase 2 SEQUOIA, the GalNAc-siRNA fazirsiran lowered its hepatocyte target in serum and in liver tissue and reduced the misfolded Z-AAT protein globules in the liver on paired pre-treatment and post-treatment biopsies.2

Already in MASH. ION224, an antisense oligonucleotide against DGAT2, met its primary endpoint in a 51-week phase 2 trial in MASH with F1 to F3 fibrosis, in 46% and 59% of patients at the two doses against 19% on placebo.3

Next. Targets in hepatic stellate cells, the cells that make the scar, follow as delivery to them matures across the field.

03 · Approach

Silence the target

The Apertome Engine scored 110k+ genes across single-cell and bulk human liver datasets and prioritized 69 cell-type-specific targets. Chemistry is matched to where each RNA sits: antisense oligonucleotides for nuclear lncRNAs, siRNA for RNA in the cytoplasm. Both chemistries have approved medicines behind them.

04 · Next milestone

Validation in human liver organoids

Each target is silenced in human liver organoids and measured for whether the scarring program switches off and reverses, and the strongest advance to in vivo models. Testing in human tissue gives early efficacy signals, and clinical studies will pair histology with non-invasive fibrosis markers.

05 · Human patient data

Tested in patient tissue first

Liver biopsiesBlood samplesClinical dataEvery disease stage

We have access to liver fibrosis patients and their biopsies, blood samples and clinical data across the stages of the disease. Every prioritized target will be tested in patient tissue before a molecule is designed.

Sources (3)
  1. 1 Angulo et al., Gastroenterology 2015 ↗Fibrosis stage, not other histologic features, is associated with long-term outcomes in NAFLD.
  2. 2 Clark et al., Gastroenterology 2024 ↗SEQUOIA: phase 2 trial of fazirsiran in alpha-1 antitrypsin deficiency liver disease.
  3. 3 ION224-CS2, Lancet 2025 ↗Phase 2 trial of ION224, an antisense oligonucleotide against DGAT2, in MASH.
Proof of concept

TILAM, a published lncRNA target in liver fibrosis (Hepatology, 2024), is expressed predominantly in the stellate cells that make the scar in the injured liver, and depleting it protected against fibrosis in human stellate cells, human liver organoids and mouse models. It is not an Apertome program; it is the benchmark ours are measured against.

Read the TILAM paper ↗
Our mission

Turning the other 98% of the genome into medicines.

We are building the company that finds and drugs the RNA controlling disease in the cells where it starts, beginning with fibrosis, the end point of chronic disease that no approved medicine switches off.

Leadership & advisors

The people behind Apertome Therapeutics

RNA discovery, drug development strategy, fundraising, product development and liver biology.
Discovery

Raza Ur Rahman, PhD

Founder & CEO
  • Built RNA discovery platforms Oasis 2, SEAweb and Singletrome
  • Co-author, TILAM discovery paper (Hepatology, 2024)
  • Harvard · Broad · MGH · UMass Chan
  • Consultant to biotech drug discovery programs
Strategy

William Glauser, PhD

Advisor
  • 20 years pharma strategy and BD
  • Former SVP Business Development, Schrödinger
  • Co-founder, Ibis Therapeutics
  • MBA Entrepreneurship · PhD Chemistry
Partnering

Nigel J. B. MacClancy, BCL

Advisor
  • Former biotech CEO, CBO & board member
  • Drug development & precision medicine
  • Fundraising, partnerships & licensing
  • Operations, portfolio management, corporate and IP law
Liver biology

Alan C. Mullen, MD, PhD

Scientific Advisor
  • Professor of Medicine, Gastroenterology, UMass Chan
  • Physician-scientist and expert in non-coding RNA in liver disease
  • Discovered TILAM, a liver fibrosis lncRNA
Error 404

Page not found.

The page you were looking for has moved or does not exist.

Legal

Privacy notice

Apertome Therapeutics collects only the information you choose to send us, such as your name, email address, organization and message when you use our contact form or email us.

We use this information to respond to your inquiry. We do not sell or share it with third parties for marketing. You can ask us to access, correct or delete your information at any time by writing to raza@apertometx.com.

Apertome Therapeutics · Boston, Massachusetts

Contact

Talk to us about Apertome.

For investment, partnership or scientific collaboration.

Email us directly raza@apertometx.com Or send a message with the form.
Apertome Therapeutics Boston, Massachusetts

{{ formError }}

Thank you.

We'll be in touch shortly.

Learn more

RNA medicines for the cells that drive fibrosis.